评论：重组人白细胞介素-1受体拮抗剂GR007在健康中国受试者中的药代动力学和安全性 - Suppr

Suppr

超能文献

Comment on: Pharmacokinetics and Safety of Recombinant Human Interleukin-1 Receptor Antagonist GR007 in Healthy Chinese Subjects.

作者信息

Srinivas Nuggehally R

机构信息

Innovation and Technology, Jubilant Life Sciences, D-12, Sector 59, Noida, Uttar Pradesh, India.

出版信息

Eur J Drug Metab Pharmacokinet. 2019 Oct;44(5):719-721. doi: 10.1007/s13318-019-00566-8.

DOI:10.1007/s13318-019-00566-8

PMID:31240570

Abstract

摘要

相似文献

Comment on: Pharmacokinetics and Safety of Recombinant Human Interleukin-1 Receptor Antagonist GR007 in Healthy Chinese Subjects.

Eur J Drug Metab Pharmacokinet. 2019 Oct;44(5):719-721. doi: 10.1007/s13318-019-00566-8.

Author's Reply to: "Comment on: Pharmacokinetics and Safety of Recombinant Human Interleukin-1 Receptor Antagonist GR007 in Chinese Healthy Subjects".

Eur J Drug Metab Pharmacokinet. 2019 Oct;44(5):723-724. doi: 10.1007/s13318-019-00574-8.

Pharmacokinetics and Safety of Recombinant Human Interleukin-1 Receptor Antagonist GR007 in Healthy Chinese Subjects.

Eur J Drug Metab Pharmacokinet. 2019 Jun;44(3):353-360. doi: 10.1007/s13318-018-0523-5.

The pharmacokinetics of interleukin-1 receptor antagonist in Chinese subjects with rheumatoid arthritis.

Pharmacol Res. 2004 Sep;50(3):371-6. doi: 10.1016/j.phrs.2004.02.002.

Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose denosumab in healthy Chinese volunteers: A randomized, single-blind, placebo-controlled study.

PLoS One. 2018 Jun 22;13(6):e0197984. doi: 10.1371/journal.pone.0197984. eCollection 2018.

Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers.

Basic Clin Pharmacol Toxicol. 2012 Feb;110(2):154-61. doi: 10.1111/j.1742-7843.2011.00768.x. Epub 2011 Aug 18.

Safety and tolerability of serelaxin, a recombinant human relaxin-2 in development for the treatment of acute heart failure, in healthy Japanese volunteers and a comparison of pharmacokinetics and pharmacodynamics in healthy Japanese and Caucasian populations.

J Clin Pharmacol. 2015 Apr;55(4):415-22. doi: 10.1002/jcph.433. Epub 2015 Feb 4.

Safety, tolerability and pharmacokinetics and pharmacodynamics of HL2351, a novel hybrid fc-fused interleukin-1 receptor antagonist, in healthy subjects: A first-in-human study.

Br J Clin Pharmacol. 2020 Feb;86(2):372-379. doi: 10.1111/bcp.14161. Epub 2020 Jan 3.

Non-Compartmental Pharmacokinetics and Safety of Single-Dose Eldecalcitol (ED-71) in Healthy Chinese Adult Males.

Clin Drug Investig. 2018 Oct;38(10):901-908. doi: 10.1007/s40261-018-0682-9.

Comparative Pharmacokinetics, Bioequivalence and Safety Study of Two Recombinant Human Chorionic Gonadotropin Injections in Healthy Chinese Subjects.

Drug Des Devel Ther. 2020 Jan 29;14:435-444. doi: 10.2147/DDDT.S235064. eCollection 2020.

引用本文的文献

Author's Reply to: "Comment on: Pharmacokinetics and Safety of Recombinant Human Interleukin-1 Receptor Antagonist GR007 in Chinese Healthy Subjects".

Eur J Drug Metab Pharmacokinet. 2019 Oct;44(5):723-724. doi: 10.1007/s13318-019-00574-8.

本文引用的文献

Pharmacokinetics and Safety of Recombinant Human Interleukin-1 Receptor Antagonist GR007 in Healthy Chinese Subjects.

Eur J Drug Metab Pharmacokinet. 2019 Jun;44(3):353-360. doi: 10.1007/s13318-018-0523-5.

Exogenous IL-1Ra attenuates intestinal mucositis induced by oxaliplatin and 5-fluorouracil through suppression of p53-dependent apoptosis.

Anticancer Drugs. 2015 Jan;26(1):35-45. doi: 10.1097/CAD.0000000000000142.

IL-1Ra selectively protects intestinal crypt epithelial cells, but not tumor cells, from chemotoxicity via p53-mediated upregulation of p21(WAF1) and p27(KIP1.).

Pharmacol Res. 2014 Apr;82:21-33. doi: 10.1016/j.phrs.2014.03.007. Epub 2014 Mar 28.

Recombinant human interleukin-1 receptor antagonist reduces acute lethal toxicity and protects hematopoiesis from chemotoxicity in vivo.

Biomed Pharmacother. 2013 Mar;67(2):108-15. doi: 10.1016/j.biopha.2012.11.002. Epub 2012 Nov 23.

Interleukin-1 receptor antagonist attenuates cyclophosphamide-induced mucositis in a murine model.

Cancer Chemother Pharmacol. 2011 Jun;67(6):1445-53. doi: 10.1007/s00280-010-1439-1. Epub 2010 Sep 3.

Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome.

Arthritis Rheum. 2010 Jan;62(1):258-67. doi: 10.1002/art.25057.

Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition.

N Engl J Med. 2006 Aug 10;355(6):581-92. doi: 10.1056/NEJMoa055137.

Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial.

Arthritis Rheum. 2003 Apr;48(4):927-34. doi: 10.1002/art.10870.

Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.

Arthritis Rheum. 2002 Mar;46(3):614-24. doi: 10.1002/art.10141.

Safety, tolerance, and pharmacokinetics of cefepime administered intramuscularly to healthy subjects.

J Clin Pharmacol. 1990 Oct;30(10):900-10. doi: 10.1002/j.1552-4604.1990.tb03569.x.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验